Amgen Completes Acquisition of KAI Pharmaceuticals; Renaissance Acquisition Holdings Acquires DPT Laboratories; and More.
Amgen has completed its acquisition of KAI Pharmaceuticals, a privately held company based in South San Francisco, California. The acquisition was initially announced Apr. 10, 2012, and includes KAI’s lead product candidate KAI-4169, a novel agent being studied initially for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease who are on dialysis. Read More
Renaissance Acquisition Holdings, a portfolio company of RoundTable Healthcare Partners, an operating-oriented private-equity firm focused exclusively on the healthcare industry, has acquired the CDMO DPT Laboratories. DPT’s headquarters and staff will continue to be located in San Antonio, Texas, and its management team will remain in place. As a result of the transaction, DFB Pharmaceuticals, based in San Antonio and Fort Worth, Texas, will maintain a meaningful interest in the combined business and will provide oversight and counsel through representation on Renaissance’s board of directors. Read More
Seven pharmaceutical companies (Abbott, AstraZeneca, Bayer, Eli Lilly, GlaxoSmithKline, Merck & Co., and Sanofi) and four research institutions (the Infectious Disease Research Institute; the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health; Texas A&M University; and Weill Cornell Medical College), working with the Bill & Melinda Gates Foundation, have launched a partnership that aims to expedite the discovery of new treatments for tuberculosis (TB). The partnership, known as the TB Drug Accelerator (TBDA), will target the discovery of new TB drugs by collaborating on early-stage research. The long-term goal of the TBDA is to create a TB drug regimen that cures patients in only one month. Existing drugs, all at least 50 years old, require six months to cure the disease-a lengthy process that contributes to 20–30% of patients dropping out before completion. Aided by nearly $20 million from the Gates Foundation, the partners launched the TBDA in April 2012, and have begun the first round of screening for new TB drug candidates. The TBDA aims to develop five new preclinical drug candidates with treatment-shortening potential within five years and proof-of-concept for a one-month, three-drug regimen within 10 years. Read More
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers. Read More
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.